You are here

Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects

Last updated on March 15, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Anaheim, California, 92801 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hepatitis, Hepatitis C
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male or female subjects at least 18 years of age.

- HCV seropositive.

- HCV RNA >10,000 IU/mL at screening.

- HCV Genotype 1. Subjects infected with a non-genotype 1 strain or mixed genotypes are
not eligible.

- Treatment naïve (no prior treatment with IFN alfa +/ RBV regimens or investigational
anti-HCV agents).

- Liver biopsy within two years (24 months) of Screening with non-cirrhotic fibrosis
classification. For those subjects with liver biopsy outside of the time window or for
those subjects with no history of liver biopsy, a biopsy must be performed prior to
randomization.

- Ultrasound within 6 months of Screening for 1) those subjects with bridging fibrosis
or 2) those subjects with AFP >50 and carcinoma. For those subjects with an ultrasound conducted outside the 6-month time
window, an ultrasound must be performed prior to randomization.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Co-infection with either HIV or HBV.

- Evidence of severe or decompensated liver disease.

- Subjects with liver disease unrelated to HCV infection.

- Pre-existing medical condition that makes the subject unsuitable for treatment with
pegIFN/RBV therapy per product labeling.

- Laboratory abnormality at Screening that makes the subject unsuitable for treatment
with pegIFN/RBV therapy per product labeling.

- Abnormal ECG suggestive of clinically significant cardiac disease or QTc>450msec.

- History of organ transplant.

- Contraindicated medications being taken by the subject at the time of randomization
that must be continued during the study period, including potent CYP3A4 inhibitors,
sensitive CYP3A4 substrates, CYP3A4 substrates with narrow therapeutic range and
CYP3A4 inducers.

- Active alcohol or substance abuse sufficient, in the Investigator's judgment, to
prevent adherence to study medication and/or follow up.

- Pregnant or nursing females.

- Males whose female partner is pregnant.

NCT00987337
Pfizer
Completed
Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
NCT03248882
All Genders
18+
Years
Multiple Sites
Hepatitis, Hepatitis C
NCT00987337
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now